title: An overview of vortioxetine.
abstract: Six clinicians provide an overview of the serotonergic antidepressant vortioxetine, which was recently approved for the treatment of major depressive disorder in adults. They discuss the pharmacologic profile and receptor-mediated effects of vortioxetine in relation to potential outcomes. Additionally, they summarize the clinical trials, which demonstrate vortioxetine's efficacy, and discuss findings related to safety and tolerability that have high relevance to patient compliance.
authors.forename: Alan F
authors.initials: AF
authors.lastname: Schatzberg
authors.forename: Pierre
authors.initials: P
authors.lastname: Blier
authors.forename: Larry
authors.initials: L
authors.lastname: Culpepper
authors.forename: Rakesh
authors.initials: R
authors.lastname: Jain
authors.forename: George I
authors.initials: GI
authors.lastname: Papakostas
authors.forename: Michael E
authors.initials: ME
authors.lastname: Thase
mesh_terms: D000818:Animals; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000494:pharmacology; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D061366:Numbers Needed To Treat; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D011320:Primary Health Care; D011985:Receptors, Serotonin / Q000187:drug effects*; D012008:Recurrence; D050486:Serotonin Plasma Membrane Transport Proteins / Q000187:drug effects; D013440:Sulfides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D000078784:Vortioxetine
chemical_list: D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D010879:Piperazines; D011985:Receptors, Serotonin; D050486:Serotonin Plasma Membrane Transport Proteins; D013440:Sulfides; D000078784:Vortioxetine